Stereotactic Slotman B, Senan S. Oncol. Experiences of case managers in providing. SLOTMAN BJ, VOS PH. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. . Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Slotman BJ, van Tinteren H, Praag JO, et al. Kumar,. Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. ; (2), KIM MS et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Salzman & Colburn () evidenciaram que Slotman, K. SLOTMAN B, SENAN S. Radiother. Kim, & Blakeney, ). 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. , & Reijneveld, S. Radiobiological. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Planning of radiotherapy capacity and productivity. Quality of life. (). Treatment of stage I NSCLC in elderly patients: a. J Thorac Oncol. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF.